CONCLUSION
Cellular Dynamics (Madison, WI) has developed a highly standardized, scalable process to manufacture human iPSC-derived cardiomyocytes.
Using this process, the company launched its iCell Cardiomyocytes product line in December 2009, whereby we can produce the
hundreds of billions of human cardiomyocytes needed by the pharmaceutical industry for drug-toxicity testing.
These iCell Cardiomyocytes demonstrate molecular and physiological properties and show sensitivity to cardiotoxic compounds
expected of human cardiomyocytes. The ability to consistently produce large numbers of high quality and high purity cardiomyocytes
offers the pharmaceutical industry a new tool to better predict the cardiotoxicity of new drug candidates. It is expected
that these cells will allow pharmaceutical companies to more efficiently select drug candidates while reducing the likelihood
that cardiotoxic activity of these compounds will manifest themselves late in development or after regulatory approval and
market launch.
Blake Anson* is iCell Cardiomyocyte product manager, Emile Nuwaysir is COO, Brad Swanson is director of cell biology product development, and Wen Bo Wang is director of process sciences, all at Cellular Dynamics International, 525 Science Drive, Madison, WI 53711.
*To whom all correspondence should be addressed.
REFERENCES
1. J. A. Thomson et al., Science 282 (539), 1061–1062 (1998).
2. K. Takahashi and S. Yamankai, Cell 126, 663–676 (2006).
3. J. Yu et al., Science 318 (5858): 1917–1920 (2007).
4. K. Takahashi et al., Cell 131, 861–872 (2007).
5. J. Q. He et al., Circ. Res. 93, 32–39 (2003).
6. J. Zhang et al., Circ. Res.104 (4) e30–41 (2009).
7. G. Narazaki et al., Circulation 118 (5),498–506 (2008).
8. N. Maherali and K. Hochedlinger, Cell Stem Cell 3, 595–605 (2008)
9. J. Yu et al., Science 324 (5928): 797–801 (2009).
10. B. Feng et al., Cell Stem Cell, 4, 301–312 (2009).
|
